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Abstract
Background: Human serum paraoxonase-1 (PON1) prevents oxidation of low density lipoprotein cholesterol (LDL-C) and
hydrolyzes the oxidized form, therefore preventing the development of atherosclerosis. The polymorphisms of PON1 gene
are known to affect the PON1 activity and thereby coronary artery disease (CAD) risk. As studies are lacking in North-West
Indian Punjabi’s, a distinct ethnic group with high incidence of CAD, we determined PON1 activity, genotypes and
haplotypes in this population and correlated them with the risk of CAD.
Methodology/Principal Findings: 350 angiographically proven ($70% stenosis) CAD patients and 300 healthy controls
were investigated. PON1 activity was determined towards paraoxon (Paraoxonase; PONase) and phenylacetate
(Arylesterase; AREase) substrates. In addition, genotyping was carried out by using multiplex PCR, allele specific
oligonucleotide –PCR and PCR-RFLP methods and haplotyping was determined by PHASE software. The serum PONase and
AREase activities were significantly lower in CAD patients as compared to the controls. All studied polymorphisms except
L55M had significant effect on PONase activity. However AREase activity was not affected by them. In a logistic regression
model, after adjustment for the conventional risk factors for CAD, QR (OR: 2.73 (1.57–4.72)) and RR (OR, 16.24 (6.41–41.14))
genotypes of Q192R polymorphism and GG (OR: 2.07 (1.02–4.21)) genotype of 2162A/G polymorphism had significantly
higher CAD risk. Haplotypes L-T-G-Q-C (OR: 3.25 (1.72–6.16)) and L-T-G-R-G (OR: 2.82 (1.01–7.80)) were also significantly
associated with CAD.
Conclusions: In conclusion this study shows that CAD patients had lower PONase and AREase activities as compared to the
controls. The coding Q192R polymorphism, promoter 2162A/G polymorphism and L-T-G-Q-C and L-T-G-R-G haplotypes are
all independently associated with CAD.
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Introduction
The oxidative modification of low-density lipoprotein choles-
terol (LDL-C) in the arterial wall is believed to be the major
pathogenetic mechanism behind the initiation and acceleration of
atherosclerosis, and thus the coronary artery disease (CAD) [1].
High-density lipoprotein cholesterol (HDL-C), on the other hand
is known to have a protective effect. The protective role of HDL-C
is believed to be mainly due to enzyme paraoxonase 1 (PON1), a
Ca
++ dependent esterase, bound to its surface which probably
prevents atherosclerosis by preventing LDL-C from peroxidation
[2]. In addition to preventing peroxidation, it also hydrolyzes the
oxidized LDL as shown in-vivo and in-vitro studies [3,4]. It has been
shown that PON1 knockout mice cannot hydrolyze the oxidized
LDL and have increased risk of developing CAD [5].
There exists a wide variation in PON1 activity in different ethnic
groups and within individuals in the same ethnic group [6]. The
PON1 activity has been shown to be lower after acute myocardial
infarction [7]. It is also lower in patients with familial hypercholes-
terolemia and diabetes mellitus, who are more prone to CAD [8].
Thishasled tothe hypothesisthat thelowerthe PON1activityis,the
higher will be the accumulation of oxidized LDL and risk of CAD.
The PON1 gene has nearly 200 SNPs (single nucleotide
polymorphisms) [9]. Of these 2909G/C [rs854572], 2162A/G
[rs705381], 2108C/T [rs705379] polymorphisms located in the
promoter and Q192R [rs662] and L55M [rs 854560] polymor-
phisms located in the coding region are the most commonly
studied SNPs. PON1 hydrolyzes a variety of organophosphates
including paraoxon (PONase), diazoxon (DZOase), sarin and
soman and arylesters such as phenylacetate (AREase) [10].
Following purification of rabbit [11] and human [12] PON1, it
was confirmed that it can hydrolyze both paraoxon and
phenylacetate [13]. PON1 Q192R polymorphism affects the
catalytic efficiency of PON1 towards some of its substrates [14].
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compared to PON1 Q192 isoform, whereas Q192 isoform
hydrolyses diazoxon, sarin and soman rapidly as compared to
R192 isoform [15]. However, phenylacetate hydrolysis i.e.
AREase activity is not affected by Q192R polymorphism and
has been shown to correspond with PON1 levels [9,16,17]
determined by immunological methods [18].
There are several studies demonstrating an association between
Q192R and L55M polymorphisms and susceptibility to CAD
[19,20]. However others have failed to find such an association
[21,22,23]. A few studies have also looked at association between
2108C/T polymorphism and risk of CAD [24]. Literature is
almost silent regarding the effect of 2909G/C, 2162A/G
polymorphisms and PON1 haplotypes on CAD risk.
The North West Indian Punjabi’s are considered to be a
progeny of many proto and post Harappan invaders who entered
lands from West and became original settlers of the area. They are
thought to be progeny of Indo – Scythian, Indo European and
Indo – Aryan stocks [25]. Singh et al. [26] have shown that
healthy North-West Indian Punjabis have lower PONase activity
as compared to Caucasian whites. In a subsequent study, in same
population it was shown that CAD patients with or without type II
diabetes mellitus have lower PONase activity as compared to
healthy controls [27]. However, information regarding PON1
coding and promoter polymorphisms in this population is not
available. In the present case-control study we investigated the
effect of PON1 polymorphisms on PON1 activity and lipid levels
in angiographically proven CAD patients. Further, we also
investigated the association of PON1 genotypes and haplotypes
with the risk of CAD in the same population.
Results
Baseline characteristics of the study population
In the CAD group, 180 patients had a single vessel involved
whereas 190 had double and 52 had triple vessel disease.
Compared to the controls, CAD group had greater proportion
of men, alcohol consumers and were significantly older, had
higher BMI and lower serum HDL-C levels (p=0.0001) (Table 1).
However no significant difference was observed in LDL-C, TG
and TC (p.0.05) between the groups (Table 1).
Serum PON1 activity in the study population
The CAD patients had significantly lower serum PONase
(113.0 nmol/min/ml vs. 178.0 nmol/min/ml) and AREase activ-
ities (74.6 mmol/min/ml vs. 82.7 mmol/min/ml) (P,0.0001) as
compared to the controls (Table 1). The HDL/PONase ratio was
significantly higher in patients (Table 1). The differences in PON1
activity (PONase and AREase) between the controls and patients
was tested for independence from other variables by a multiple
linear regression analysis. The model included age, BMI, sex,
smoking, alcohol consumption, HDL-C, LDL-C, TG, TC,
Q192R, 2909 G/C, 2162A/G and 2108C/T polymorphisms.
The difference in PONase activity was found to be dependent on
differences in BMI (P=0.0001), coding Q192R (P=0.0001),
promoter 2909G/C (P=0.0001), 2162A/G (P=0.0001) and
2108C/T (P=0.001) polymorphisms (Table 2). However AREase
activity was found to be independent of these polymorphisms
(P.0.05) (data not shown).
Effect of PON1 polymorphisms on PON1 activity
Figure 1 shows the effect of the PON1 Q192R polymorphism on
PONase activity across Q192R genotypes in controls and CAD
patients. The PONase activity in patients ranged from 21.30 to
307.5 nmol/min/ml and from 28.5 to 410.0 nmol/min/ml in
controls. PONase activity was significantly lower in QQ homozy-
gotes followed by QR heterozygotes and RR homozygotes
(QQ,QR,RR) in patients (95.0,113.0,165.0 nmol/min/ml)
and controls (165.0,189.0,248.4 nmol/min/ml) (Fig. 1). It
provides an excellent example of why substrates whose rates of
hydrolysis are affected by the PON1 Q192R polymorphism should
not be used to compare levels across genotypes. Figure 2 shows
PON1 levels estimated by AREaseactivity acrossQ192R genotypes
for controls and CAD patients. The AREase activity in controls
ranged from 22.8 to 293.0 mmol/min/ml and, in patients from
15.28 to 149.0 mmol/min/ml. The median PON1 levels, were
similar across Q192R genotypes for controls (QQ=82.63,
QR=82.59 and RR=83.04 mmol/min/ml) and CAD patients
(QQ=76.21, QR=71.52 and RR=70.16 mmol/min/ml).
L55M polymorphism had no effect on serum PONase and
AREase activities in both the groups. However when comparison
was carried out between groups within genotypes, both activities
was significantly lower in LL, LM and MM genotypes in CAD
patients as compared to the controls (Table 3). PONase activity
was affected by promoter 2909G/C, 2162A/G and 2108C/T
polymorphisms in both controls and patients (Table 3). It was
highest in wild GG (2909G/C), AA (2162A/G) and CC
(2108C/T) homozygotes and lowest in variant CC (2909G/C),
GG (2162A/G) and TT (2108C/T) homozygotes, whereas
heterozygotes GC (2909G/C), AG (2162A/G) and CT (2108C/
Table 1. Demographic, clinical and biochemical
characteristics of Controls and CAD patients.
Variables Controls (n=300) CAD (n=350)
Age (yrs) 43.1610.7 55.969.7*
Male/Female (n) 151/149 286/64*
BMI (kg/m
2) 23.564.1 27.163.9*
SBP (mm Hg) 120.9610.7 129615.4*
DBP (mm Hg) 8066.9 8567.7*
Alcohol consumers 18 (6.0%) 86 (24.6%)
Non consumers 282 (94.0%) 264* (75.4%)
Smokers 50 (16.7%) 73 (20.9%)
Non-Smokers 250 (83.3%) 277 (79.1%)
HDL-C, mmol/L 1.2360.20 1.0860.26*
LDL-C, mmol/L 2.3060.51 2.3760.89
TG, mmol/L 1.5360.63 1.5060.57
TC, mmol/L 4.3261.08 4.4361.27
PONase activity
(nmol/min/ml)
178.0 (28.5–410.0) 113.0* (21.30–307.5)
AREase activity
(mmol/min/ml)
82.7 (22.8–293.0) 74.6* (15.2–149.0)
HDL-C/PONase ratio 7.8610
2364610
23 12.2*610
2365.6610
23
Number of diseased
vessels
Single vessel, n (%) ------ 108 (30.9%)
Double vessel, n (%) ------ 190 (54.4%)
Triple vessel, n (%) ------ 52 (14.6%)
Values are mean 6 SD or median (range).
*P,0.0001 vs. controls.
BMI: body mass index; TG: triglycerides; TC: total cholesterol; PONase:
Paraoxonase; AREase: Arylesterase.
doi:10.1371/journal.pone.0017805.t001
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activity was not affected by any of these promoter polymorphisms
(Table 3). When comparison was carried out between groups
within genotypes, patients had lower PONase and AREase
activities in all genotypes as compared to the controls (Table 3).
Effect of PON1 polymorphisms on lipid levels
HDL-C was significantly lower (P,0.05) in QQ (Q192R), and
GG (2162A/G) genotypes and TG was significantly higher
(P,0.05) in GG (2909G/C) and RR (Q192R) genotypes in
patients as compared to controls. No significant difference was
observed for LDL-C and TC in any of the group (data not shown).
Association of coding Q192R and L55M polymorphisms
with CAD
The genotype and allele frequency distribution of coding Q192R
andL55MpolymorphismsofCADpatientsandcontrolsisshownin
Table 4. All the studied polymorphisms in patients and controls
Table 2. Multiple linear regression analysis for PONase activity.
Variables
Unstandardized
coefficients
Standardized
coefficient (b) t P value
B Std. Error
Age 20.016 0.217 20.003 20.074 0.941
Sex 3.060 5.165 0.019 0.592 0.554
Q192R 34.140 3.349 0.310 10.193 0.000
2909G/C 215.753 3.100 20.157 25.082 0.000
2162A/G 219.797 3.186 20.191 26.214 0.000
2108C/T 219.646 3.167 20.191 26.204 0.000
Smoking status .941 6.053 0.005 0.156 0.876
Alcohol status 3.843 6.593 0.019 0.583 0.560
BMI 22.187 0.578 20.123 23.781 0.000
HDL-C 0.176 0.242 0.023 0.728 0.467
LDL-C 20.096 0.080 20.037 21.205 0.229
TG 0.086 0.044 0.061 1.975 0.06
TC 0.012 0.050 0.008 0.248 0.804
Groups 253.498 6.243 20.357 28.570 0.000
BMI: body mass index; TG: triglycerides; TC: total cholesterol.
doi:10.1371/journal.pone.0017805.t002
Figure 1. Individual data point for PONase activity in Controls and CAD patients for each PON1 Q192R genotype. Medians are
indicated by crossbars.
doi:10.1371/journal.pone.0017805.g001
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Q192R polymorphism, QR and RR genotypes were significantly
associated with CAD (P=0.0001) with ORs being 2.08 (95% CI:
1.49–2.90) and 2.92 (95% CI: 1.71–4.98) respectively as compared
to wild QQ homozygotes. The frequency of minor R allele in
patients was significantly higher (0.39) in patients as compared to
Figure 2. Individual data point for AREase activity in Controls and CAD patients for each PON1 Q192R genotype. Medians are
indicated by crossbars.
doi:10.1371/journal.pone.0017805.g002
Table 3. PONase and AREase activities in Controls and CAD patients according to their coding L55M and promoter 2909G/C,
2162A/G, and 2108C/T polymorphisms.
L55M Controls CAD
LL LM MM LL LM MM
PONase activity
(nmol/min/ml)
186.0
(47.4–410.0)
156.0
(28.5–398.0)
150.0
(123.0–231.0)
111.0
1
(21.0–307.5)
116.0
1
(21.0–256.0)
85.65
I
(64.5–93.0)
AREase activity
(nmol/min/ml)
82.8
(22.8–293.0)
81.7
(51.3–134.2)
83.5
(61.0–107.0)
76.1
1
(17.07–149.0)
70.7
1
(15.20–132.3)
75.8
(61.22–88.6)
2909G/C GG GC CC GG GC CC
PONase activity
(nmol/min/ml)
195.0
(47.4–389.0)
174.0
(59.6–410.0)
163.8
*
(28.5–398.0)
134.7
1
(21.0–307.5)
123.2
1
(21.0–307.5)
74.4
*1
(21.0–264.0)
AREase activity
(nmol/min/ml)
84.4
(22.8–134.2)
82.4
(22.9–293.0)
81.1
(40.3–115.6)
76.1
1
(15.2–132.3)
73.0
1
(15.2–125.0)
75.4
I
(17.0–149.0)
2162A/G AA AG GG AA AG GG
PONase activity
(nmol/min/ml)
198.0
(59.6–410.0)
178.0
(28.5–389.0)
160.5
{
(38.2–398.0)
146.5
1
(35.6–295.0)
123.0
1
(21.0–307.5)
88.0
{1
(21.0–274.7)
AREase activity
(nmol/min/ml)
82.6
(22.8–293.0)
82.67
(46.0–115.6)
83.0
(40.3–112.5)
71.4
1
(38.2–149.0)
75.3
1
(15.2–132.3)
76.1
1
(15.2–97.6)
2108C/T CC CT TT CC CT TT
PONase activity
(nmol/min/ml)
214.5
(53.3–410.0)
170.5
(50.1–367.0)
144.5
{
(28.5–398.0)
142.5
1
(37.4–307.5)
112.6
1
(21.0–248.5)
86.7
{1
(21.0–289.2)
AREase activity
(nmol/min/ml)
80.8
(22.8–293.0)
83.4
(55.8–134.23)
83.0
(51.3–115.0)
78.0
I
(33.9–110.0)
75.6
1
(15.2–149.0)
71.3
1
(15.27–98.79)
Values are median (range).
*Significantly different from GG+GC genotype P,0.0001;
{Significantly different from AA+GG genotype p,0.0001;
{Significantly different from CC+CT genotype P,0.0001;
1Significantly different from controls P,0.0001;
ISignificantly different from controls P,0.05.
doi:10.1371/journal.pone.0017805.t003
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polymorphism, genotype and allele frequency distribution was not
significantly different (P.0.05) between the groups.
Association between Q192R polymorphism and CAD was
followed up with multiple logistic regression to determine if the
association was independent of other known risk factors for CAD,
such as alcohol consumption, HDL-C levels, age, and sex. In the
regression analysis, age, sex, alcohol consumption, HDL-C levels
and BMI were associated with CAD. The association between
Q192RpolymorphismandCADpersistedinthisanalysis.TheORs
were 2.73 (95% CI: 1.57–4.72) and 16.24 (95% CI: 6.41–41.14) for
QR heterozygote and RR homozygote respectively (Table 5).
Association of Promoter 2909G/C, 2162A/G and
2108C/T polymorphisms with CAD
In promoter 2909G/C polymorphism, GC and CC genotypes
weresignificantly associated with CAD(P=0.0001) with ORs being
1.80 (95% CI: 1.24–2.59) and 3.03 (95% CI: 1.96–4.68) respectively
(Table 4) as compared to wild GG homozygote. The frequency of
minor C allele in patients was significantly higher (0.54) as
compared to that in controls (0.39) (OR: 2.15; 95% CI: 1.53–
3.03). In 2162A/G polymorphism, AG and GG genotypes were
significantly associated with CAD (P=0.0001) with ORs being 2.12
(95% CI: 1.41–3.12) and 3.43 (95% CI: 2.19–5.38) respectively
(Table 4) as compared to wild AA homozygote. The frequency of
minor G allele in patients was significantly higher (0.60) as
compared to that in controls (0.44) (OR: 2.50; 95%CI: 1.72–
3.64). In 2108C/T polymorphism, CT and TT genotypes were
also significantly associated with CAD (P=0.001) with ORs being
1.74 (95% CI: 1.19–2.55) and 2.84 (95% CI: 1.83–4.40) respectively
(Table 4) as compared to wild CC homozygote. The frequency of
minor T allele in patients was significantly higher (0.57) as
compared to that in controls (0.43) (OR: 2.07; 95% CI: 1.45–2.90).
However after multiple logistic regression analysis in which
cardiovascular risk factors were adjusted, the association was
observed only with 2162A/G polymorphism and CAD with OR
being 2.07 (95% CI: 1.02–4.21) for GG homozygotes (Table 6). No
significant association was observed with other two promoter
polymorphisms (2909G/C and 2108C/T) (P.0.05) (data not
shown).
Table 4. PON1 coding (Q192R, L55M) and promoter (2909G/
C, 2162A/G and 2108C/T) genotypes and allele frequencies
distribution in Controls and CAD patients.
SNPs Controls CAD OR 95% CI
P
value
Q192R
genotypes
QQ* 168 (56%) 127 (36.3%) 1 .00 - -
QR 108 (36%) 170 (48.6%) 2.08 1.49–2.90 0.0001
RR 24 (8.0%) 53 (15.1%) 2.92 1.71–4.98 0.0001
Allele
frequency
Q* 0.74 0.61 1.00
R 0.26 0.39 2.23 1.61–3.06 0.0001
L55M
genotypes
LL 193 (64.3%) 247 (70.6%) 1.92 0.53–6.89 0.31
LM 101 (33.7%) 99 (28.3%) 1.47 0.40–5.36 0.56
MM* 6 (2.0%) 4 (1.1%) 1.00 -
Allele
frequency
L 0.81 0.85 1.76 0.49–6.31 0.38
M* 0.19 0.15 1.00
2909G/C
genotypes
GG* 118 (39.3%) 80 (22.9%) 1.00 -
GC 129 (43%) 160 (45.7%) 1.80 1.24–2.59 0.002
CC 53 (17.7%) 110 (31.4%) 3.03 1.96–4.68 0.0001
Allele
frequency
G* 0.61 0.46 1.00
C 0.39 0.54 2.15 1.53–3.03 0.0001
2162A/G
genotypes
AA* 97 (32.3%) 56 (16.0%) 1.00
AG 141 (47%) 171 (48.9%) 2.12 1.41–3.12 0.0001
GG 62 (20.7%) 123 (35.1%) 3.43 2.19–5.38 0.0001
Allele
frequency
A* 0.56 0.40 1.00
G 0.44 0.60 2.50 1.72–3.64 0.0001
2108C/T
genotypes
CC* 100 (33.3%) 68 (19.4%) 1.00
CT 140 (46.7%) 166 (47.4%) 1.74 1.19–2.55 0.001
TT 60 (20%) 116 (33.1%) 2.84 1.83–4.40 0.0001
Allele
frequency
C* 0.57 0.43 1.00
T 0.43 0.57 2.07 1.45–2.90 0.0001
*Reference Category; OR: odds ratio; CI: confidence interval.
doi:10.1371/journal.pone.0017805.t004
Table 5. Multiple logistic regression analysis of Q192R
polymorphism and association with CAD.
Variables B S.E. OR 95% CI
P
value
Age 0.11 0.01 1.11 1.08–1.14 0.0001
Sex-Female* 1.000 - -
Male 1.08 0.27 2.95 1.70–5.10 0.0001
PONase activity 20.01 0.002 0.98 0.97–0.98 0.0001
AREase activity 20.02 0.009 0.97 0.96–0.99 0.001
Alcohol consumer-never* 1.000
Current 1.32 0.39 3.77 1.74–8.12 0.001
SBP 0.04 0.01 1.04 1.02–1.07 0.001
HDL-C 20.06 0.01 0.94 0.91–0.96 0.0001
BMI 0.11 0.03 1.12 1.05–1.20 0.0001
Q192R-QQ* 1.00 - -
QR 1.00 0.28 2.73 1.57–4.72 0.0001
RR 2.78 0.47 16.24 6.41–41.14 0.0001
*Reference Category; OR: odds ratio; CI: confidence interval. BMI: body mass
index; TG: triglycerides; TC: total cholesterol; PONase: Paraoxonase; AREase:
Arylesterase.
doi:10.1371/journal.pone.0017805.t005
PON1 Polymorphisms and CAD
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LD values were generated to look for association among the five
polymorphisms. No significant LD was observed among the
PON1 SNPs with D’ value ranging from 0.03 to 0.25 (Table 7).
Association of PON1 haplotypes with CAD
On haplotype analysis we observed 32 different combinations of
these coding and promoter polymorphisms (Table S1). The
frequencies of haplotypes L-T-G-Q-C and L-T-G-R-G (each with
four variant and one wild allele) was significantly higher in CAD
patients and they were found to be associated with higher risk of
CAD with ORs being 3.25 (95% CI: 1.72–6.16) and 2.82 (95%
CI: 1.01–7.80) respectively. Frequencies of haplotypes L-C-A-Q-G
(with one variant and four wild alleles) (OR=0.16; 95% CI: 0.08–
0.31), L-T-A-Q-G (with two variant and three wild alleles)
(OR=0.51; 95% CI: 0.27–0.96), and M-C-A-Q-G (with all wild
alleles) (OR=0.16; 95% CI: 0.03–0.76) were significantly lower in
patients as compared to the controls.
Discussion
The susceptibility of developing CAD in Asian Indians is 3–4
times higher than Caucasians, 6-times higher than Chinese, and
20-times higher than Japanese [28,29] and they tend to develop it
at a younger age [30,31]. There are several studies which have
investigated the relationship between genetic variability of PON1
and risk of disease. Unfortunately, most of these studies have
looked for association of PON1 SNPs with susceptibility and have
ignored the more important factor, serum PONase activity
[19,32]. Differences in PON1 activity between populations of
the same ethnic group are well known [6], which, if not taken into
account, could have affected the results of case-control studies.
However, PON1 activity alone is not a good measure of risk of
disease as activity is markedly affected by the Q192R polymor-
phism. Mackness et al. [33] with other PON1 investigators [15,34]
strongly suggest that all further case-control studies should include
measurement of the enzyme and its genetic polymorphisms. In this
case-control study, we examined both PON1 activity and PON1
polymorphisms. In addition, we also investigated the effect of
polymorphisms on serum PON1 activity and lipid levels.
Previous studies that have investigated the relationship between
PON1- Q192R polymorphism and CAD have produced inconsis-
tent results. Wheeler et al. [32] in a meta analysis of 35 studies
showed that 192R variant was associated with increased risk of
CAD with relative risk being 1.12 (95%CI: 1.07–1.16). Mackness et
al. [33] in another meta-analysis observed an increased frequency of
the PON1 192R allele in CAD patients. However, Schmidt et al.
[20] in his study failed to find such an association though they
observed that atherosclerotic lesions were more common in RR
genotype than QR or QQ genotype. In this study we found that
192R allele frequency was significantly higher in patients and
192QR and 192RR variants were associated with increased risk of
CAD with risk being 2.73 (95% CI: 1.57–4.72) and 16.24 (95% CI:
6.41–41.14) respectively, afteradjustingallconventional risk factors.
Several studies have shown that there are racial differences in
association between Q192R polymorphism and CAD risk.
Sanghera et al. [35] found that Q192R polymorphism was
associated with CAD in Singapore Indians, but not in Singapore
Chinese. Zama et al. [36] observed a positive association of Q192R
polymorphism in CAD patients in Japanese. Ko et al. [37] in
Taiwan population, compared the Q192R genotype distribution in
CAD patients with age and sex-matched controls and found no
significant difference in the two groups. Similarly Suehiro et al. [38]
observed no association in Japanese subjects.
We found lower PON1 activity towards paraoxon (PONase)
substrate in CAD patients as compared to the controls, with results
being similar to prospective epidemiological Caperhilly [39] study.
The low PONase activity is a predictive risk factor for CAD,
independent of all other established risk factors such as age, sex,
smoking, alcohol and HDL-C levels (Multiple linear regression
analysis). These findings indicate that PONase activity plays an
important role in the pathogenesis of CAD. However, PONase
activity was significantly affected by Q192R polymorphism. It was
significantlyhigher in RR homozygote and lower in QQ homozygote,
in both groups. This observation is similar to other studies [40,41].
PON1 activity is not affected towards phenylacetate (AREase)
substrate across Q192R polymorphism [16]. Richter et al. [9]
have stated that measurement of AREase activity of PON1 or
determination of PON1 protein levels by ELISA are the minimum
measures that should be carried out in any epidemiological study.
Table 6. Multiple logistic regression analysis of 2162 A/G
polymorphism and association with CAD.
Variables B S.E. OR 95% CI
P
value
Age 0.10 0.01 1.11 1.08–1.13 0.0001
Sex-Female* 1.000 - -
Male 1.06 0.26 2.90 1.72–4.89 0.0001
PONase activity 20.01 0.002 0.98 0.98–0.99 0.0001
AREase activity 20.02 0.008 0.97 0.95–0.99 0.001
Alcohol consumer-never* 1.000
Current 1.45 0.38 4.29 2.02–9.08 0.001
SBP 0.04 0.01 1.04 1.02–1.07 0.001
HDL-C 20.06 0.01 0.93 0.91–0.96 0.0001
BMI 0.11 0.03 1.12 1.05–1.20 0.0001
2162A/G-AA* 1.00 - -
AG 0.54 0.31 1.72 0.93–3.19 0.08
GG 0.73 0.36 2.07 1.02–4.21 0.04
*Reference Category; OR: odds ratio; CI: confidence interval. BMI: body mass
index; TG: triglycerides; TC: total cholesterol; PONase: Paraoxonase; AREase:
Arylesterase.
doi:10.1371/journal.pone.0017805.t006
Table 7. Pair wise comparison of measures of LD (D’) for the
polymorphisms of PON1 gene.
Variant 1 Variant 2 D’
2909G/C (rs 854572) 2162A/G (rs 705381) 0.21
2909G/C (rs 854572) 2108 C/T (rs 705379) 0.22
2909G/C (rs 854572) L55M (rs 854560) 0.09
2909G/C (rs 854572) Q192R (rs 662) 0.03
2162A/G (rs 705381) 2108 C/T (rs 705379) 0.15
2162A/G (rs 705381) L55M (rs 854560) 0.10
2162A/G (rs 705381) Q192R (rs 662) 0.10
2108 C/T (rs 705379) L55M (rs 854560) 0.03
2108 C/T (rs 705379) Q192R (rs 662) 0.12
L55M (rs 854560) Q192R (rs 662) 0.25
doi:10.1371/journal.pone.0017805.t007
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lower in patients and was not affected by the Q192R
polymorphism and can be considered a surrogate measure of
PON1 levels across Q192R genotypes. This has been used in a
number of previous studies [9,16,17,42].
Fewer studies have been conducted into the relationship
between the PON-L55M polymorphism and CAD but again with
inconsistent results [43]. Blatter et al. [44] and Mackness et al. [45]
found that L55M polymorphism had significant effect on PON1
activity independent of Q192R polymorphism. We could not
observe any significant effect of L55M polymorphisms with CAD
and PON1 activity. This is unlike the study by Schmidt et al. [20]
who observed an independent association of CAD with L55M
polymorphism in Austrian CAD patients.
To the best of our knowledge, not much information is available
in literature in terms of PON1 promoter polymorphisms, PON1
activity and CAD risk. We found that PONase activity was
significantly higher in wild AA (2162 site), GG (2909 site) and
CC (2108C/T site) homozygotes. It increased in the order of the
GG,AG,AA genotypes within the 2162 A/G polymorphism,
CC,CG,GG genotypes in 2909G/C polymorphism and
TT,CT,CC genotypes within 2108C/T polymorphisms in
patients and controls. These observations are similar to other
studies [46,47,48,49]. In-vitro expression studies reveal that
2108C/T polymorphism has a significant effect on expression
of PON1 gene as 2108C/T polymorphism lies within GGCGGG
consensus sequence, which is the binding site for the sp1
transcription factor [50]. Najafi et al. [24] reported an association
between 2108C/T polymorphism and CAD. Leviev et al. [51]
observed that 2108CC genotype protected against the risk of
CAD in patients aged 60 or younger (OR: 0.60; 95% CI: 0.37–
0.90) but not in older patients. In our study we observed that 2108
C/T polymorphism was not associated with CAD risk after
adjusting for conventional risk factors. 2909GC (OR: 1.80; 95%
CI: 1.24–2.59) and 2909CC (OR: 3.03; 95% CI: 1.96–4.68)
genotypes of 2909G/C polymorphism were associated with CAD
risk. Significantly higher distribution of 2909C allele in CAD
patients (OR: 2.15; 95% CI: 1.53–3.03) was observed as compared
to controls. The 2162AG (OR: 2.12; 95% CI: 1.41–3.12) and
2162GG genotypes (OR: 3.43; 95% CI: 2.19–5.38) of 2162A/G
polymorphism were also significantly higher in CAD patients.
However on multiple logistic regression analysis, only 2162GG
genotype was independently associated with increased risk of CAD
after adjustment for conventional risk factors for CAD. Our study
showed that among the studied polymorphisms of PON1 gene,
only coding Q192R and promoter 2162A/G polymorphisms
were independent genetic markers for CAD.
AREase activity was not affected by any of the promoter
polymorphisms in any group. These results indicate that AREase
activity is a better enzymatic test for examining the association
between PON1 activity and disease, especially when genotyping
cannot be done. In some studies linkage disequilibrium has been
observed between PON1 polymorphism at position 55 with that at
position 192 [52]. The 2108C/T and 2909G/C have been
observed to be in linkage disequilibrium with each other.
However, no linkage disequilibrium has been observed between
PON1 192 polymorphism and 2108C/T and 2909G/C
polymorphisms [53]. In our study we found no linkage
disequilibrium in studied SNPs with D’ value ranging from 0.03
to 0.25 indicating individual SNPs have an independent
association with disease. Our results are similar to that of Jarvik
et al. [54] who also did not observe any linkage disequilibrium
across the PON1 gene SNPs.
Determination of haplotypes is gaining attention because
multiple linked SNPs have the potential to provide significantly
more power to genetic analysis than individual SNPs [55].
Information is lacking regarding PON1 haplotypes and CAD risk.
We determined haplotype frequencies of coding and promoter
polymorphisms by using PHASE software to impute PON1
haplotypes based on genotype information. We observed that L-
T-G-Q-C(carrying4variant and 1wild type allele)andL-T-G-R-G
(carrying 4 variantand1 wild typeallele)haplotypes wereassociated
with 3.2 and 2.8 fold increase in the risk of CAD. Haplotypes M-C-
A-Q-G (carrying all wild typeallele),L-T-A-Q-G (carrying2 variant
and 3 wild type allele) and L-C-A-Q-G (carrying 1 variant and 4
wild type allele) were more prevalent in controls with 0.16, 0.51 and
0.16 odds ratio respectively and could be protective of CAD.
In a study of the Hutterite Brethren, a North American
population isolated by religious belief, the PON1 genotype was
significantly associated with variation in the concentration of
HDL-C, LDL-C, TG and apo-B [56]. In them, homozygotes (low-
activity variant) of PON1 had significantly lower TG level, LDL-C
and apo-B than heterozygotes and homozygotes for the high-
activity variant. However we could not find any major effect of
PON1 genotypes on lipid levels both in controls and patients.
In conclusion CAD patients had lower PONase and AREase
activities as compared to the controls. The coding Q192R,
promoter 2162A/G polymorphisms and L-T-G-Q-C and L-T-G-
R-G haplotypes are all independently associated with CAD.
Strength and Limitations
The present study has several strengths and limitations that
need to be addressed briefly. The strengths include the use of a
pure Punjabi population from the North-West region of India to
eliminate false positive results due to population stratification.
Angiographical profiles of all subjects were evaluated. Regarding
limitations, we could not stop statins in CAD patients due to
ethical reasons. As statins are known to influence PON1 activity
[57], we cannot rule out that they may be having some role in
altering PON1 activity in CAD patients. We derived PON1 levels
across Q192R genotypes indirectly from AREase activity. Ideal
would have been measure it directly by ELISA. However, as it was
suggested by several investigators that AREase activity can be used
as measure of PON1 levels [9,16,17,58] we used this. In addition,
identifying significant associations of genetic variants with complex
qualitative trait, such as CAD may demand a larger sample size
than for quantitative traits to arrive at worthwhile conclusion.
Further studies may be required with more numbers as our study
was limited by relatively small groups.
Materials and Methods
Subject Selection
Between August 2007 and September 2009, 350 North-West
Indian Punjabi’s with angiographically proven CAD at Nehru
hospital , Postgraduate Institute of Medical Education and
Research, Chandigarh (India) were included in the study. Patients
with diabetes mellitus, cirrhosis of liver, COPD, HIV infection,
malnutrition and acute myocardial infarction were excluded from
the study. We also excluded those patients who had undergone a
recent coronary intervention i.e. angioplasty or bypass. The disease
severity was determined by counting the number of affected three
major epicardial coronary arteries with significant stenosis ($70%).
The angiogram was assessed by at least two cardiologists who were
unaware of the patient’s status before inclusion in the study. In
addition, relevant history was recorded regarding risk factors for
CAD such as smoking, alcohol consumption, presenceor absence of
PON1 Polymorphisms and CAD
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of onset and medical treatment. Due to ethical reasons it was not
possible to stop treatment including statins in patients. The dose of
atorvastatin varied from 20–80 mg/day with majority on 40 mg. In
the control group, 300 North-West Indian Punjabi’s who were
attending a general medical clinic for health check up and were
found to be healthy were included.
Ethics Statement
All the subjects were provided with the study protocol and an
informed written consent was obtained. The study was approved
by the institute (Postgraduate Institute of Medical Education and
Research) ethics committee.
Biochemical analysis
Venous blood sample was collected from both controls and
CAD patients between 8.30 and 9.30 AM after an overnight fast.
The serum was isolated by low-speed centrifugation and
enzymatic assays were carried out. The lipid profile (HDL-C,
LDL-C, TG and TC) was measured by enzymatic method using
autoanalyzer (Hitachi modular P) and Roche diagnostic kits. The
PON1 activity and level were measured by using paraoxon and
phenylacetate (Sigma Chem,USA) as substrates respectively with
activity was measured by a modification of method described by
Mackness et al. [6] and level by Eckerson’s method [12].
Genotyping
The DNA was extracted from the blood cells by method
described by Daly et al. [59] and was stored at 220uC till
genotyping. A total of 5 SNP’s of PON1 gene (Accession
No. AC004022) were selected for the present study. Coding
Q192R [rs662] and L55M [rs854560] genotyping was carried out
by PCR amplification and restriction digestion [60]. The promoter
2909G/C (rs 854572) and 2108C/T (rs 705379) SNP’s were
genotyped by multiplex PCR whereas 2162A/G (rs 705381) SNP,
genotyping was carried out by allele specific oligonucleotide-PCR
[61]. The primers were designed using PRIMER 3 software.
Details of primer sequences, PCR conditions and product size are
shown in Table S2. The PCR products were run on 2% agarose
gel and were visualized by ethidium bromide staining. The PCR
reagents were purchased from Fermentas, Lithuania where as
primers were obtained from Operon, USA. For detailed
description of this section please see Text S1.
Statistical analysis
Statistical analysis was carried out using SPSS (Version 17.0)
software. All the study variables are shown as mean 6 standard
deviation or median (range) depending on the shape of the
distribution curve. Student’s t-test or Mann-Whitney U test was
used to compare the data between controls and CAD patients.
The demographic parameters were correlated with CAD by
univariate logistic regression analysis, and followed up with
multiple logistic regression analysis for significant variables. A
multiple linear regression analysis was undertaken to determine
the independence of PON1 activity from other variables.
The genotype and allele frequencies for each polymorphism were
stratified for homozygote wild, heterozygote and homozygote
variant type of the respective allelic variant and Pearson’s x
2 test
wasused forcomparisonbetween groups.Thegenotypicassociation
with CAD and their odds ratio (OR) with 95% confidence interval
was estimated by binary logistic regression, where homozygous wild
type was kept as a reference. The effect of genetic variants on CAD
susceptibility was determined by multiple logistic regression analysis
after adjusting the conventional risk factors. Power of the sample
size was calculated using the PAWE software [62]. P values were
subjected to Boneferroni’s correction and considered significant
when P,0.05. The study had more than 80% statistical power to
detect an association. Linkage disequilibrium for PON1 polymor-
phisms was measured using Haploview (Version 4.2) software
(http://www.broad.mit.edu/mpg/haploview/contact.php) and
was expressed in terms of D’. The haplotype frequency was
determined by PHASE (Version 2.1) software (http://stephenslab.
uchicago.edu/software.html). Fisher’s exact test was used to find
differences in haplotype frequency between CAD patients and
controls. A p value#0.05 was considered significant.
Supporting Information
Table S1 The haplotypes frequency distribution in Controls and
CAD patients for coding (Q192R, L55M) and promoter (2909G/
C, 2162A/G, 2108C/T) SNPs of PON1 gene.
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